**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | SABCS CSP | **Project Code** | PB4VCS113 |
| **Virtual Project Manager** | Meg Quick | **Clinical Program Manager** | Amy Furedy |
| **Compliance** | Briana Devaser | **Editor** | Christi Gray |

**Launch Date/Internal Launch Date:**

December 22, 2014

**Project Type**

Video

Downloadable Slides

Other:

\*no newsflash\*

**Email Blast Included?**

Yes

No

Subject Line:

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests:

**Cross Promotion**

Yes

No

If Yes, List Activities:

Oncology Guru,

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

**CME?**

Yes

No

Webcast/PDS URL:

**www.primeoncology.org/2014\_sanantonio\_csp**

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title: 2014 CSP San Antonio**

**Listing Page**

**[Insert small CSP Graphic to the left]**

**[TITLE]**

Clinical Spotlight From the 2014 Annual Breast Cancer Meeting in San Antonio

**[DATE** | **LOCATION]**

December 2014 | San Antonio, Texas

**Landing Page**

**[Insert CSP Graphic header]**

**LEFT SIDE**

**[Insert Text below]**

Clinical Spotlight From the 2014Annual Breast Cancer Meeting in San Antonio

**Activity Features**

**[Insert icon]** Expert Discussion

**[Insert icon]** Downloadable Slides

**[Insert icon]** CME-Certified

**RIGHT SIDE**

**ACTIVITY OVERVIEW**

View CME-certified expert discussion and downloadable slides regarding exciting new data on breast cancer released at the 2014 Annual Breast Cancer Meeting in San Antonio.

**CONTINUING EDUCATION**

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of X.XX *AMA PRA Category 1 Credit(s)™*. Physicians should claim only credit commensurate with the extent of their participation in the activity.

**[Tab- BC]**

Discussants:

**Louis Chow, MD,** Organisation for Oncology and Translational Research (OOTR), Hong Kong, China

**Luca Gianni, MD,** San Raffaele Institute**,** Milan, Italy

**Andreas Schneeweiss, MD**, National Center for Tumor Diseases, University Hospital

Heidelberg, Germany

Featured Abstracts:

**Abstract #S2-07: A Randomized Phase III Trial Comparing Neoadjuvant Chemotherapy With Weekly Nanoparticle-Based Paclitaxel With Solvent Based Paclitaxel Followed by Anthracyline/Cyclophosphamide for Patients With Early Breast Cancer (GeparSepto); GBG 69**

**Abstract #S3-06: Mutational Analysis of CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Weekly Paclitaxel (T) and Trastuzumab (H) With or Without Lapatinib (L) for HER2-Positive Breast Cancer**

**Abstract #P3-11-01: Neoadjuvant Chemotherapy With or Without Bevacizumab or Everolimus: Survival Analysis of The HER2-Negative Cohort of the GEPARQUINTO Study (GBG 44)**

**Abstract #P3-11-16 S0800: Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer (NCI CDR0000636131)**

**Learning Objectives**

After successful completion of this educational activity, participants should be able to:

* Summarize the key new data and important developments in neoadjuvant therapy for patients with breast cancer
* Discuss how these data are likely to influence current and future practice
* Understand the influences of biological characteristics (eg, ER and HER2 status) on treatment selection and likelihood of response
* Describe best practices for treatment selection and patient management in the neoadjuvant setting

**[Button] View**

**CME Information Pop-Up**

**Release Date**

December 22, 2014

**Expiration Date**   
December 22, 2015

**Faculty**  
**Louis Chow, MD**

Organisation for Oncology and Translational Research (OOTR)

Hong Kong, China

**Luca Gianni, MD**

San Raffaele Institute

Milan, Italy

**Andreas Schneeweiss, MD**

National Center for Tumor Diseases

University Hospital

Heidelberg, Germany

**Learning Objectives [USE SAME AS ABOVE]**

**Provider**  
This activity is provided by prIME Oncology.

**Support**  
This educational activity is supported by a grant from Celgene Corporation.

**Target Audience**

This educational activity is designed for medical oncologists, surgical and radiation oncologists, and other healthcare professionals involved and/or interested in the management of patients with breast cancer.

**Continuing Medical Education**  
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of *XX AMA PRA Category 1 Credits*™*.*Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Method of Participation**  
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the [Terms of Use](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx).

A link to the posttest is available on the video player page.

**In order to receive credit, participants must successfully complete the online posttest with XX% or higher.**

**Disclosure of Relevant Financial Relationships**   
prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

**Faculty Disclosures-**  
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr

Dr

Dr Scheeweiss has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

* Robert E. Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – expert testimony for Novartis
* Amy Furedy, RN, OCN (clinical content/planner) – no relevant financial relationships
* Christi Gray (editorial content reviewer) – no relevant financial relationships
* Briana Devaser (compliance) – no relevant financial relationships

**Disclosure of Unlabeled Use**  
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

**Disclaimer**  
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

**Player Page-BC**

**[Insert CSP Graphic header]**

**[INSERT VIDEO and SLIDE PRESENTATION]**

**[Include a banner below the player that says: Click the thumbnails above to advance through the reference slide deck]**

**[Buttons-Downloadable Slides & View Newsflash & Evaluate and Claim Credit]**

**ACTIVITY OVERVIEW**

View CME-certified expert discussion and downloadable slides regarding exciting new data on breast cancer released at the 2014 Annual Breast Cancer Meeting in San Antonio.

**FEATURED EXPERTS**

**[Insert Photo] Louis Chow, MD** Organisation for Oncology and Translational Research (OOTR)

Hong Kong, China

**[Insert Photo] Luca Gianni, MD** San Raffaele Institute Milan, Italy

**[Insert Photo] Andreas Schneeweiss, MD**  
 National Center for Tumor Diseases  
 University Hospital

Heidelberg, Germany

**FEATURED ABSTRACTS [SAME AS ABOVE]**

**TARGET AUDIENCE [SAME AS ABOVE]**

**LEARNING OBJECTIVES [SAME AS ABOVE]**

**SUPPORT STATEMENT [SAME AS ABOVE]**